Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2021 07:00 ET | Source: Nkarta, Inc.

Nkarta to Present at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
June 14, 2021 07:01 ET | Source: Nkarta, Inc.

Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term

SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
May 25, 2021 07:30 ET | Source: Nkarta, Inc.

Nkarta Announces June 2021 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today...
May 13, 2021 16:02 ET | Source: Nkarta, Inc.

Nkarta Reports First Quarter 2021 Financial Results and Business Progress

NKX019 IND received FDA clearance; NKX019 patient dosing expected to start in 2H 2021Protocol amendment to ongoing NKX101 clinical trial adds a second multi-dosing regimen and a shorter waiting period...
April 28, 2021 08:02 ET | Source: Nkarta, Inc.

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

NKX019 to be Nkarta’s second CAR NK pipeline program to enter clinical trial SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company...
March 25, 2021 16:03 ET | Source: Nkarta, Inc.

Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress

Continued progress in dosing of patients in clinical trial of NKX101, investigational CAR NK cell therapy engineered with NKG2D receptor, in acute myeloid leukemia (AML) and myelodysplastic syndrome...
February 17, 2021 16:03 ET | Source: Nkarta, Inc.

Nkarta Announces February and March 2021 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
November 12, 2020 16:03 ET | Source: Nkarta, Inc.

Nkarta Reports Third Quarter 2020 Financial Results

First patient dosed in clinical trial of NKX101, investigational NK cell therapy engineered with NKG2D-targeted CAR, in acute myeloid leukemia and myelodysplastic syndromesIND application for NKX019...
November 12, 2020 16:02 ET | Source: Nkarta, Inc.

Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
November 09, 2020 08:02 ET | Source: Nkarta, Inc.

Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right